Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21742636 | 0.89 | CYP11B1 (0.54) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL21742831 | 0.87 | CYP11B1 (0.53) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL30714540 | 0.85 | AXL (0.56) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL1439800 | 0.85 | AXL (0.56) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL13537064 | 0.83 | MKNK1 (0.52) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL12237053 | 0.82 | CYP2A6 (0.51) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL16593136 | 0.81 | CYP11B1 (0.53) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL2377996 | 0.80 | MKNK1 (0.58) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL18745701 | 0.80 | MKNK1 (0.72) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL225149 | 0.79 | CYP2A6 (0.68) | MKNK1MKNK2MEN1PSIP1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | claimed |
| EP-1846372-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1846372-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-24 | — | — | EP | claimed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | claimed |
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8592486-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-1846372-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1846372-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | MKNK1 3896/4885MKNK2 4092/4885MEN1 3772/4885 |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | CXCL8, CCR8, CXCR2 | MKNK1 3896/4885MKNK2 4092/4885MEN1 3772/4885 |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | MKNK1 3896/4885MKNK2 4092/4885MEN1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.